NCT00400348View on ClinicalTrials.gov

Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

November 30, 2008

Conditions
Ovarian Cancer
Interventions
DRUG

Panzem Nanocrystal Colloidal Dispersion (NCD)

Panzem NCD 1,000 mg, four times daily for 28 consecutive days

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY